A

AstraZeneca

Global pharmaceutical company developing prescription medicines

Senior Scientist

Full-TimePosted on 10/2/2026Deadline 11/1/26
No salary listed
Senior
Master's, PhD
Macclesfield, UK
HybridAt least three days per week in the office.

About the job

Requirements
  • PhD, or MSc with equivalent industrial experience, in pharmaceutical sciences, chemistry, materials science, spectroscopy or a related discipline, together with significant experience in pharmaceutical development.
  • Deep expertise in molecular-level characterisation and interpretation of complex pharmaceutical materials, particularly amorphous, disordered, heterogeneous or multi-component systems, and the ability to connect molecular structure, composition and interactions to material behaviour and product performance.
  • Broad hands-on experience in pharmaceutical solid-state characterisation, including integrating complementary datasets and selecting fit-for-purpose methods for mechanistic understanding and routine control.
  • Strong understanding of how material attributes, solid-state properties and molecular interactions influence drug substance and drug product developability, including stability, manufacturability, dissolution, performance and control strategy.
  • Ability to operate across the interpretive chain from data analysis and molecular mechanism to product implication and practical control, framing the right question and choosing the right approach.
  • Proven ability to lead scientific activities within multidisciplinary teams, solve complex problems, prioritise effectively and deliver high-quality outcomes.
  • Strong communication skills and the ability to translate complex datasets into clear scientific conclusions and actionable development recommendations.
  • Digital fluency and curiosity, with the ability to use modern data, computational, automation and AI-enabled tools to improve scientific understanding and accelerate project delivery.
Responsibilities
  • Lead and deliver solid-state science activities underpinning drug product projects, ensuring delivery to agreed milestones, with a particular focus on complex amorphous and disordered systems across oral and inhalation platforms.
  • Define and drive the identification of Critical Molecularly Driven Material Attributes across drug substances, excipients and intermediate drug products, and assess their impacts on product performance and manufacturing process robustness.
  • Design and conduct laboratory-based experimental activities to assess solid-state risks and probe drug–excipient interactions to define material control strategies.
  • Deconvolute how material attributes influence product performance through processes such as wetting, hydration, disintegration, swelling, gel formation, molecular dissolution, supersaturation, precipitation and recrystallisation, and provide a solid-state and materials perspective on biopharmaceutical performance in collaboration with biopharmaceutics and drug product colleagues.
  • Investigate how molecular descriptors of materials, component interactions or processing conditions influence particle or heterogeneous-system formation, phase distribution, internal gradients and surface composition, using chemically, spatially and time-resolved approaches where appropriate.
  • Translate mechanistic understanding into practical material, process and product-performance control, distinguishing advanced mechanistic methods from fit-for-purpose control methods that are reproducible, transferable and suitable for stability and continuous manufacturing environments.
  • Drive digital-first strategies and apply in silico approaches, such as molecular modelling, informatics, chemometrics, generative models or simulations, alongside experimental work to accelerate development decisions and predict solid-state behaviour and its impact on product performance.
  • Represent solid-state science on drug product projects, collaborating with analysts, formulators and process engineers at the drug substance–drug product interface to integrate risk-based material strategies into product design and drive innovation, robustness and regulatory readiness.
  • Engage with external partners to extend capability, oversee outsourced work, and support material characterisation and method transfer as needed.
  • Author and review technical documentation, including development reports and contributions to CMC regulatory submissions, health-authority responses and briefing documents aligned to intensified regulatory expectations on solid-state attributes and excipient performance.
  • Contribute to developing the global solid-state community by acting as coach and mentor, giving timely feedback, and advancing the science through internal knowledge-sharing and external collaboration.
Desired Qualifications
  • Practical and theoretical expertise in solid-state NMR, particularly applied to molecular interactions, local environments, molecular mobility, phase behaviour or amorphous systems.
  • Familiarity with polymorph screening, complex form landscapes and crystalline form selection as complementary context to the primary focus on complex and disordered systems.
  • Experience supporting higher molecular weight or otherwise complex molecules and formulations, with an understanding of how molecular architecture and physical-state behaviour influence developability and product performance.
  • Understanding of the relationship between solid-state properties, dissolution and solution behaviour, including supersaturation, precipitation, aggregation, colloidal association and phase transformations.
  • Experience investigating material evolution during processing, storage or use through advanced, in situ, spatially resolved or time-resolved characterisation, including granulation, compaction, drying, coating, spray drying or extrusion.
  • Experience applying computational or data-driven approaches such as Python, scripting, informatics, chemometrics, multivariate analysis, predictive modelling, generative AI or automated scientific workflows.
  • Experience with external partners, CMC regulatory authoring, technology transfer or work in GLP/GMP or other highly regulated environments.
  • Evidence of scientific excellence through publications, patents, conference presentations or contribution to scientific communities.

About the company

AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Get referred to AstraZeneca

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sept. 29, 2026 FDA filing for Orpathys-Tagrisso targets EGFR-mutated MET-overexpressing lung cancer.
  • Oct. 2026 Medicare-negotiation appeal keeps AstraZeneca fighting for U.S. pricing power.
  • July 2026 Tagrisso appellate win preserved a blockbuster and validated its patent moat.

What critics are saying

  • Forxiga patents face France, Portugal, and Poland challenges, with an October 2026 trial.
  • Lynparza faces Canadian generics in October 2026, threatening near-term ovarian-cancer revenue.
  • Tagrisso and Forxiga patent losses would puncture AstraZeneca's cash engines before 2027.

What makes AstraZeneca unique

  • Sept. 28, 2026 Summit deal extends AstraZeneca's ADC leadership into PD-1/VEGF combinations.
  • July 2026 CLARITY-Gastric01 strengthened sonesitatug vedotin, reinforcing AstraZeneca's GI oncology franchise.
  • Sept. 25, 2026 baxdrostat registration shows durable cardiovascular depth beyond oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

↑ 6%

1 year growth

↑ 6%

2 year growth

↑ 9%
MedCity News
Sep 29th, 2026
AstraZeneca places a $2B bet on a Summit Therapeutics cancer drug.

AstraZeneca places a $2B bet on a Summit Therapeutics cancer drug. AstraZeneca's equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical companies testing the pairing of antibody drug conjugates with PD-1/VEGF bispecific antibodies, a drug combination that could offer advantages in cancer treatment. By Frank Vinluan on September 29, 2026 3:25 pm AstraZeneca is making a $2 billion equity investment in Summit Therapeutics, a business deal that also kicks off a research collaboration that could pursue multiple drug combinations with an initial focus on gastrointestinal cancers. The deal announced after Monday's market close is a vote of confidence in the Summit cancer drug ivonescimab, a bispecific antibody designed to bind to two targets, PD-1 on T cells and VEGF on cancer cells. Several oncology-focused pharmaceutical companies have already struck deals to add such drugs to their pipelines. Summit's late-clinical drug gives AstraZeneca access to a contender in the class. Ivonescimab was developed by China-based Akeso Therapeutics. Phase 3 trial results in lung cancer raised hopes for the molecule as data showed it beat Merck's blockbuster PD-1 inhibitor Keytruda in a head-to-head study. But those results were from a trial in China, where the drug has approvals in lung cancers and is marketed by Akeso. For Summit, ivonescimab's prospects ride on the results of clinical trials the company is conducting in outside of China. Summit holds rights to the drug in North and South America, Europe, the Middle East, Africa, and Japan. We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey. AstraZeneca is a leader in the development and commercialization of antibody drug conjugates (ADCs) for cancer. The Summit deal gives AstraZeneca the opportunity to test its experimental ADC sonesitatug vedotin (sone-ve) in combination with ivonescimab. In July, AstraZeneca reported sone-ve led to statistically significant improvement in overall survival, meeting the main goal of a Phase 3 test in CLDN18.2-positive gastric cancers. Detailed trial results are scheduled for presentation at the upcoming European Society for Medical Oncology conference in late October. This medical meeting will also include the presentation of data for ivonescimab in biliary tract cancer. Last month, Summit reported preliminary Phase 3 results showing statistically significant improvement. This pivotal study was conducted by Akeso in China. Drug resistance is one limitation of ADCs, but PD-1/VEGF bispecific antibodies may be able to help. In addition to bringing two distinct approaches to cancer, the dual mechanism also makes the tumor microenvironment more favorable to ADCs, which is hoped to overcome resistance. The potential advantages of combining PD-(L)1/VEGF bispecific antibodies with an ADC has led to a flurry of dealmaking to explore such drug pairings. AbbVie, Bristol Myers Squibb, Merck, Pfizer, and have struck business deals for bispecific antibodies in this class. Biotech companies are also striking deals. Late last year, Crescent Biopharma licensed a Kelun Biopharma ADC it plans to test in combination with its PD-1/VEGF bispecific antibody. AstraZeneca's new collaboration could extend beyond sone-ve. The Summit deal includes a non-binding memorandum of understanding that permits additional clinical trials testing ivonescimab in combination with other AstraZeneca cancer drugs, including other ADCs. presented by We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring. "A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumor types with combinations alongside next-generation immunotherapies," Susan Galbraith, AstraZeneca executive vice president, oncology hematology R&D, said in a prepared statement. AstraZeneca's Summit investment lends additional validation to the class of bispecific PD-(L)1/VEGF antibodies, Leerink Partners analyst Daina Graybosch said in a research note. But she also characterized the deal as "more tepid than an outright acquisition," adding that while the collaboration may lead AstraZeneca to invest more in Summit, it's also possible the pharma company learns from the trials and then licenses a competing drug in the class. That strategy has precedent. Graybosch pointed to a TROP2-targeting ADC that Merck licensed from Kelun. The deal happened after Merck reviewed data from clinical trials it conducted in collaboration with AstraZeneca and Gilead Sciences. Astrazeneca's agreement with Summit calls for the pharma company to buy about 108,955 shares of its new partner for $18.36 each, representing an 18.6% premium over Monday's closing stock price. The companies will jointly contribute to the costs of the planned clinical trials, which they expect will be sponsored by AstraZeneca. Each company also retains development and commercialization rights to its respective molecules. The deal is expected to close by the end of this week.

Affärsvärlden
Sep 29th, 2026
AstraZeneca seeks US approval for lung cancer combination.

AstraZeneca seeks US approval for lung cancer combination. The pharmaceutical company AstraZeneca has submitted an application to the FDA for approval of Orpathys in combination with Tagrisso for locally advanced or metastatic EGFR-mutated lung cancer with MET overexpression or amplification after prior EGFR-directed treatment. Today 11:15 This is stated in a press release from the partner Hutchmed. The application is supported by the phase 3 study SAFFRON, in which the combination improved both progression-free and overall survival compared with platinum-based doublet chemotherapy. Orpathys (with the active substance savolitinib) is being developed jointly through a global collaboration between AstraZeneca and Hutchmed. AstraZeneca 1,677.50 SEK +1.64% (+27.0 SEK)

AstraZeneca
Sep 28th, 2026
AstraZeneca invests $2B in Summit Therapeutics to advance cancer ADC combination strategy

AstraZeneca has announced a $2 billion equity investment in Summit Therapeutics to advance cancer treatment combinations. The investment will give AstraZeneca approximately 12% of Summit's outstanding common stock. The companies have entered a clinical collaboration to evaluate sonesitatug vedotin, a Claudin-18.2 antibody drug conjugate, combined with ivonescimab, a bispecific antibody targeting PD-1 and VEGF, in gastrointestinal cancers. Trials are set to begin imminently. Each company will retain development and commercial rights to their respective medicines whilst jointly contributing to trial costs. The collaboration aims to broaden AstraZeneca's ADC portfolio across multiple tumour types. AstraZeneca recently reported positive results from the CLARITY-Gastric01 trial for sonesitatug vedotin in advanced gastric cancers, with results to be presented at a 2026 medical congress.

MarketScreener
Sep 28th, 2026
Summit Therapeutics Inc. and astrazeneca enter into clinical trial collaboration to evaluate ivonescimab in combination with sonesitatug vedotin in multiple gastrointestinal cancers.

Summit Therapeutics Inc. and astrazeneca enter into clinical trial collaboration to evaluate ivonescimab in combination with sonesitatug vedotin in multiple gastrointestinal cancers. Published on 09/28/2026 at 05:30 pm EDT S&P Capital IQ Summit Therapeutics Inc. entered into a clinical collaboration agreement with AstraZeneca to evaluate sonesitatug vedotin in combination with ivonescimab with the intent to start studies in certain gastrointestinal (GI) cancer settings imminently. Under the terms of the clinical collaboration agreement, each company will contribute their respective compound for the combination studies to be conducted, and the parties will jointly contribute to the costs of such studies, which are intended to be sponsored by AstraZeneca. Each company will retain development and commercial rights to their respective molecules. Moreover, Summit and AstraZeneca intend to evaluate ivonescimab with an additional set of AstraZeneca?s cancer medicines, including other antibody drug conjugates (ADCs). The companies intend to share clinical development costs of potential future studies. Each company will retain their current development and commercial rights to their respective molecules, and the agreement is mutually non-exclusive. There are no additional financial considerations associated with milestones, royalties, revenue-sharing, or profit-sharing. The Memorandum of Understanding with respect to the potential clinical trial collaboration between Summit and AstraZeneca is non-binding, and there can be no assurances that the intended clinical trial collaboration comes to fruition. (C) S&P Capital IQ - 2026

University of Arkansas for Medical Sciences
Sep 25th, 2026
College of Pharmacy recognized at national convention.

College of Pharmacy recognized at national convention. By Benjamin Waldrum Sept. 25, 2026 | The UAMS College of Pharmacy's student chapter of the Student National Pharmaceutical Association (SNPhA) received an award at its annual convention in August, and several pharmacy students were recognized with individual honors. SNPhA is the official student association of the National Pharmaceutical Association (NPhA). Goodlow posing with a placard listing her as a candidate for public relations liaison, for which she was later elected. This year, the UAMS student chapter received an award for 20% membership growth, notable for a smaller chapter. This year's delegates were third-year students Lynn Duncan, Marissa Bones, Ma'Kyah Goodlow, and Mackenzie Rodgers, along with second-year students Tykia Rankin and Bryce Piper-Eason. "It was an incredible experience," Goodlow said. "We all had a wonderful time networking, learning, and representing UAMS on the national stage." Goodlow was elected as the SNPhA national public relations liaison and was a finalist in AstraZeneca's Medical Science Liaison competition. Goodlow, Duncan, and Piper-Eason participated in the CVS Health Leadership Academy. Rodgers was nominated to serve on the Nominations Committee next year, which helps select and vet key leadership positions. "I am incredibly proud to see our students recognized nationally," said Kendrea Jones, Pharm.D., the chapter's co-advisor. "Their accomplishments reflect the mission of SNPhA to support the professional development of pharmacy students while improving the health of underserved communities. These students have demonstrated leadership, professional growth and a commitment to service throughout the year, and their national recognition is a wonderful reflection of their hard work and the strength of our UAMS chapter." Rodgers, the chapter president this year, worked alongside representatives from around the country to vet candidates for the SNPhA National Executive Board, including candidates from Region 4, which includes Arkansas. "I am incredibly blessed and grateful to serve on this committee engaging with the future pharmacists of the nation," Rodgers said. "I'm thankful for the many connections made at the conference and highly encourage students to take any opportunity to attend a conference at least once throughout your academic career - you never know who you will meet."